Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amphastar Pharmaceuticals, Inc. (AMPH : NSDQ)
 
 • Company Description   
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.

Number of Employees: 2,028

 
 • Price / Volume Information   
Yesterday's Closing Price: $24.03 Daily Weekly Monthly
20 Day Moving Average: 408,289 shares
Shares Outstanding: 46.49 (millions)
Market Capitalization: $1,117.28 (millions)
Beta: 0.77
52 Week High: $49.53
52 Week Low: $20.39
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.69% -0.97%
12 Week -19.44% -22.78%
Year To Date -35.28% -43.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11570 SIXTH STREET
-
RANCHO CUCAMONGA,CA 91730
USA
ph: 909-980-9484
fax: 909-980-8296
jasons@amphastar.com http://www.amphastar.com
 
 • General Corporate Information   
Officers
Jack Yongfeng Zhang - Chief Executive Officer and President
Mary Z. Luo - Chairman and Chief Operating Officer
William J. Peters - Chief Financial Officer
Jacob Liawatidewi - Executive Vice President
Gayle M. Deflin - Director

Peer Information
Amphastar Pharmaceuticals, Inc. (BGMR)
Amphastar Pharmaceuticals, Inc. (BBIO)
Amphastar Pharmaceuticals, Inc. (IPAH)
Amphastar Pharmaceuticals, Inc. (BRL)
Amphastar Pharmaceuticals, Inc. (BHC)
Amphastar Pharmaceuticals, Inc. (AKRXQ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-GENERIC DRG
Sector: Medical
CUSIP: 03209R103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/26/26
Share - Related Items
Shares Outstanding: 46.49
Most Recent Split Date: (:1)
Beta: 0.77
Market Capitalization: $1,117.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.91 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $3.09 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/26/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 7.79
Trailing 12 Months: 7.96
PEG Ratio: -
Price Ratios
Price/Book: 1.44
Price/Cash Flow: 4.80
Price / Sales: 1.54
EPS Growth
vs. Year Ago Period: -4.60%
vs. Previous Quarter: 10.67%
Sales Growth
vs. Year Ago Period: 0.33%
vs. Previous Quarter: 9.99%
ROE
09/30/25 - 19.70
06/30/25 - 20.76
03/31/25 - 22.20
ROA
09/30/25 - 9.17
06/30/25 - 9.68
03/31/25 - 10.40
Current Ratio
09/30/25 - 3.12
06/30/25 - 3.29
03/31/25 - 2.95
Quick Ratio
09/30/25 - 2.21
06/30/25 - 2.21
03/31/25 - 2.02
Operating Margin
09/30/25 - 20.55
06/30/25 - 21.32
03/31/25 - 22.22
Net Margin
09/30/25 - 15.43
06/30/25 - 18.64
03/31/25 - 19.38
Pre-Tax Margin
09/30/25 - 18.76
06/30/25 - 22.40
03/31/25 - 23.64
Book Value
09/30/25 - 16.71
06/30/25 - 16.07
03/31/25 - 15.82
Inventory Turnover
09/30/25 - 2.04
06/30/25 - 2.19
03/31/25 - 2.44
Debt-to-Equity
09/30/25 - 0.78
06/30/25 - 0.80
03/31/25 - 0.80
Debt-to-Capital
09/30/25 - 43.93
06/30/25 - 44.51
03/31/25 - 44.56
 

Powered by Zacks Investment Research ©